Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is underway and expected to initiate in the fourth quarter of 2024 Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases


